Approval · Notice of Compliance 11944 · 2010
FEMARA: Notice of Compliance 11944
Issued December 17, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11944
- Date
- December 17, 2010
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Fulfillment of commitments as per the Letters of Undertaking dated April 1, 2005 and September 18, 2006 for the extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy and for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer, respectively
- Therapeutic class
- Non-steroidal aromatase inhibitor / Inhibitor of estrogen biosynthesis / Antitumor agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FEMARA | Not yet assigned | — |
Medicinal ingredients
- LETROZOLE 2.5 MG per TAB